|
|
|
 |
|
 |
|
Products
Therapeutics
Available Immediately to Proceed with Process Development
- Erythropoietin (EPO)
- Granulocyte Colony Stimulating Factor (G-CSF)
- Granulocyte/Macrophage Colony Stimulating Factor (G-CSF)
- Follicle Stimulating Hormone (FSH)
- Human Growth Hormone
- Luteinizing Hormone (LH)
- Interferon Alpha (IFNα)
- Interferon Beta (IFNβ)
- Interferon Gamma (IFNγ)
- Tumor Necrosis Factor Receptor (TNFR:Fc)
- α-D-Galactosidase
- Hepatitis B Vaccine Antigen
Cytokines
Available Immediately to Proceed with Process Development
- Interleukin-2 (IL-2)
- Interleukin-3 (IL-3)
- Interleukin-4 (IL-4)
- Interleukin-6 (IL-6)
- Interleukin-10 (IL-10)
- Interleukin-12 (IL-12)
- Hepatocyte Growth Factor (HGF)
- Tumor Necrosis Factor-alpha (TNFα)
- Transforming Growth Factor-beta 3 (TGF β 3)
- Vascular Endothelial Growth Factor (VEGF)
|
|
 |
|
 |
|
